Please login to the form below

Not currently logged in
Email:
Password:

transplant

This page shows the latest transplant news and features for those working in and with pharma, biotech and healthcare.

Merck’s backing of NGM Bio yields NASH drug deal

Merck’s backing of NGM Bio yields NASH drug deal

It causes fatty build-up and fibrosis in the liver, sometimes leading to cirrhosis and the need for a liver transplant, and so far has no approved treatments with some analysts

Latest news

More from news
Approximately 8 fully matching, plus 200 partially matching documents found.

Latest Intelligence

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    That said, for thalassemia, and for sickle cell, we believe these are potentially one-time curative treatments, because these stem cell transplants have been shown to last a very long time, ... Conventional stem cell transplants cost anywhere between $500

  • Health on instalment Health on instalment

    Distasteful but…. In addition to pay-for-performance, other possible funding strategies under consideration include mandatory price limits; re-insurance (currently used for expensive transplant operations); risk pooling; and lease-like

  • Can value-based healthcare take off and reach for the skies? Can value-based healthcare take off and reach for the skies?

    way under the cost-effective price and significantly lower than the current standard of allogenic stem cell transplant that costs $500, 000-800, 000 in the first year with follow-up

  • Cell and gene therapies: on course for commercial success? Cell and gene therapies: on course for commercial success?

    Many cell therapies require additional, costly procedures for administration such as an allogeneic stem cell transplant as well as adjuvant therapies. ... Many transplant centres in England, and in other countries, are funded with a single, fixed payment

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    NASH and biosimilars. One therapeutic indication that could be seen to be gaining much attention was NASH, which is the fastest growing cause of liver cancer and liver transplant in the

More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 11 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...

Infographics